Genetic variants in congenital long-QT disease genes are found in 10-15% of patients with drug-associated Torsades de Pointes, predominantly in genes encoding ancillary subunits.
No takes yet. Share an insight, caveat, or question.
May inform targeted genetic evaluation in aLQTS; leaves open prospective validation for risk stratification.
Yang et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: